Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

UNI-BIO SCIENCE GROUP LIMITED
聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

VOLUNTARY ANNOUNCEMENT
APPOINTMENT OF GROUP CHIEF BUSINESS OFFICER

Hong Kong, 11 November 2026 — The board of directors (the "**Board**") of Uni-Bio Science Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that Mr. Watson Cheng ("**Mr. Cheng**") has been appointed as Chief Business Officer of the Group ("**CBO**") with effect from 11 November 2026.

Mr. Cheng has extensive experience in biopharmaceutical investment, mergers and acquisitions, licensing and cross-border strategic partnerships. Prior to joining the Group, Mr. Cheng served as Head of International Business at ClinActiv, Head of Healthcare at Harvest Investments, Vice President of Investment at CBC Group and Director of Management Consulting at IQVIA. His previous project experience includes acquisitions of product portfolios from multinational pharmaceutical companies, the development of innovative asset platforms, the privatization of a North American listed company and the establishment of business platform, covering product in-licensing, asset integration, strategic investment and financing.

The Group continues to pursue its strategic transformation towards innovation-driven growth by advancing overseas regulatory registration and commercialization of its core products and expanding its next-generation innovative product pipeline through in-house research and development, technology in-licensing and strategic partnerships. The Group will also continue to expand its presence across retail pharmacies, e-commerce platforms and other out-of-hospital channels, strengthen its retail and e-commerce capabilities, and create new avenues for growth.

Upon assuming his role, Mr. Cheng will be primarily responsible for the Group's business development and strategic partnerships, with a focus on maximizing the value of the Group's product and pipeline portfolio, identifying and securing key products, innovative technologies and pipeline assets with strategic synergies, advancing overseas out-licensing, joint development and commercialization of its products and pipeline assets, and pursuing

strategic investments, mergers and acquisitions, resource integration and other business partnerships to support the Group's international expansion and long-term strategic development.

The Board believes that Mr. Cheng's extensive experience in biopharmaceutical investment, cross-border partnerships and business platform development, together with his responsibilities as Chief Business Officer, will help the Group expand its international partnership network, integrate strategic and commercial resources, advance the development of innovative products and strengthen its commercialization capabilities, thereby supporting the Group's long-term sustainable growth.

The Board welcomes Mr. Cheng to his new role.

On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 11 November 2026

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman), Mr. Zhao Zhi Gang (Chief executive) and Dr. Wen Yalei (Chief Operating Officer); two non-executive Directors, Mr. Yau Kwok Wing Tony and Ms. Zhang Qing; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.

* *For identification purpose only*